A detailed history of Citigroup Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 51,881 shares of AKRO stock, worth $1.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,881
Previous 29,269 77.26%
Holding current value
$1.7 Million
Previous $686,000 116.91%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.45 - $29.34 $485,027 - $663,436
22,612 Added 77.26%
51,881 $1.49 Million
Q2 2024

Aug 12, 2024

SELL
$18.31 - $24.62 $4.14 Million - $5.57 Million
-226,165 Reduced 88.54%
29,269 $686,000
Q1 2024

May 10, 2024

BUY
$17.76 - $31.18 $1.19 Million - $2.09 Million
66,982 Added 35.54%
255,434 $6.45 Million
Q4 2023

Feb 09, 2024

BUY
$11.38 - $50.33 $1.05 Million - $4.63 Million
91,962 Added 95.31%
188,452 $4.4 Million
Q3 2023

Nov 09, 2023

BUY
$41.19 - $52.25 $986,706 - $1.25 Million
23,955 Added 33.03%
96,490 $4.88 Million
Q2 2023

Aug 10, 2023

SELL
$36.89 - $56.88 $2.25 Million - $3.47 Million
-60,982 Reduced 45.67%
72,535 $3.39 Million
Q1 2023

May 11, 2023

BUY
$37.27 - $50.24 $1.88 Million - $2.54 Million
50,458 Added 60.75%
133,517 $5.11 Million
Q4 2022

Feb 09, 2023

BUY
$33.44 - $54.8 $2.7 Million - $4.43 Million
80,860 Added 3677.13%
83,059 $4.55 Million
Q3 2022

Nov 10, 2022

SELL
$10.15 - $34.05 $19,061 - $63,945
-1,878 Reduced 46.06%
2,199 $75,000
Q2 2022

Aug 10, 2022

SELL
$8.0 - $15.01 $69,936 - $131,217
-8,742 Reduced 68.2%
4,077 $39,000
Q1 2022

May 12, 2022

SELL
$12.97 - $22.26 $480,214 - $824,176
-37,025 Reduced 74.28%
12,819 $182,000
Q4 2021

Feb 10, 2022

BUY
$19.87 - $26.24 $368,846 - $487,093
18,563 Added 59.34%
49,844 $1.05 Million
Q3 2021

Nov 10, 2021

BUY
$18.65 - $25.46 $583,390 - $796,414
31,281 New
31,281 $699,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.52B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.